by Raymond T. Chung and Thomas F. Baumert
N Engl J Med 2014; 370:1576-1578, April 24, 2014
3 pp. 362 kB:
Chronic hepatitis C is a major cause of liver cirrhosis and hepatocellular carcinoma worldwide. Some 130 million to 170 million people, or about 3% of the world’s population, are chronically infected with the hepatitis C virus (HCV). The development of direct-acting antiviral agents (DAAs) has revolutionized HCV treatment by offering genuine prospects for the first comprehensive cure of a chronic viral infection in humans. This success can be traced to important scientific, clinical, and regulatory developments. Although they have achieved spectacular response rates in late-stage clinical trials, DAAs must fulfill their promise in the real world.